NOBELPHARMA COMPANIES'S POSITION ON EXPANDED ACCESS

Nobelpharma Co., Ltd. ("Nobelpharma") and Nobelpharma America LLC ("Nobelpharma America") (collectively the "Nobelpharma Companies") are committed to developing and providing safe and effective therapies to patients in need, with a focus on rare disorders. We strive to contribute to society by developing drugs and medical devices for diseases that other pharmaceutical companies may overlook because of the small number of patients affected, and to deliver these drugs and devices where they are needed.

We believe that clinical trials are the most appropriate way for patients to access investigational medical products developed by Nobelpharma. In these trials, the safety and efficacy of the investigational medical products are rigorously assessed by Nobelpharma and the relevant regulatory agencies in order to understand the investigational medical products' benefits, risks and appropriate use, including whether or not they should be approved as a therapy for their intended use. Obtaining regulatory approval enables us to bring safe and effective investigational medical products to the greatest number of patients who may benefit from treatment.

Currently, the Nobelpharma Companies do not offer, and have no plan to offer, expanded access for use of its investigational medicinal products and we are not accepting requests from healthcare providers for expanded access use. We recognize that terminology for describing expanded or early access varies. We broadly think of expanded access programs as including, for example, pre-approval access, managed access programs, expanded access programs, compassionate use, etc.

The Nobelpharma Companies may revise this position as its clinical development programs progress and reassess the approach to early access, including expanded access programs. Should patients, families, or physicians have any questions, please contact Nobelpharma Co., Ltd., the parent company of the Nobelpharma Companies, through its website at https://www.nobelpharma.co.jp/en/contact/general-form/.